University of Alabama at Birmingham

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Alabama at Birmingham sits in the top decile of US sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count).

1,160 total trials 216 currently recruiting 723 completed early-phase tilt top decile by trial count

University of Alabama at Birmingham: 1,160 sponsored US clinical trials, 216 recruiting.

University of Alabama at Birmingham sponsors 1,160 registered US clinical trials on ClinicalTrials.gov, 216 of them currently recruiting, and 723 completed. 97 of these trials are in Phase 3-4 (later-stage) and 259 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.

Top-decile sponsor footprint

University of Alabama at Birmingham ranks in the top decile of sponsors by registered trial count (#26 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 62/100

723 of 812 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,160 total, page 15 of 24

COMPLETED NA

Constraint-induced Movement Therapy to Improve Gait and Mobility of People With Chronic Stroke

NCT03114046

COMPLETED NA

Peripheral Vision Training Study

NCT03141164

TERMINATED NA

Carbon Fiber Implants

NCT03382041

COMPLETED NA

Impact of Exercise in Parkinson's Disease

NCT03495193

COMPLETED

Novel Biomarkers of Preeclampsia, Aquaporin, Fatty Acid, and S110B

NCT03567551

TERMINATED Phase 2

Nitrite Infusion in Islet Cell Transplantation

NCT03544242

COMPLETED NA

Southeastern Collaboration to Improve Blood Pressure Control

NCT02866669

COMPLETED Phase 2

Race, Natriuretic Peptides and Physiological Perturbations

NCT03070184

COMPLETED Phase 4

Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations

NCT03256799

COMPLETED Phase 2

The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor

NCT03085485

COMPLETED NA

The Influence of Bone Allograft Particle Sizes on the Quantity and Quality of New Bone Formation in Grafted Extraction Sockets and Edentulous Ridges

NCT03468998

COMPLETED NA

Racial Differences in the Natriuretic Peptide Response to Glucose Challenge

NCT03072602

COMPLETED NA

Precision High-Intensity Training Through Epigenetics (PHITE)

NCT03380923

COMPLETED NA

Advanced Virtual Exercise Environment Device for Use by Persons With Physical Disabilities

NCT02990507

COMPLETED NA

Improving Family Quality of Life Through Training to Reduce Care-Resistant Behaviors by People With AD and TBI

NCT03734289

COMPLETED NA

From Clinic to Community: An Information and Communication Technology (ICT) Home-Based Exercise Training System for Translating Clinical Findings

NCT03108950

COMPLETED Phase 2

Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions

NCT02903446

COMPLETED Phase 4

PTC Study to Evaluate Ataluren in Combination With Ivacaftor

NCT03256968

COMPLETED

Rare Diseases Clinical Research Network: Neurophysiological Correlates

NCT03077308

COMPLETED

Acute Kidney Injury in Patients With Sickle Cell Disease

NCT03105271

COMPLETED NA

In Vivo Experience With NRT to Increase Adherence and Smoking Abstinence

NCT02938403

COMPLETED Phase 4

A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis

NCT03022617

COMPLETED NA

Partnership Optimizes Weight Management in Primary Care

NCT02959021

COMPLETED NA

Virtual Reality by Mobile Phone: Improving Child Pedestrian Safety

NCT02948400

COMPLETED NA

Self-Sampling for Human Papillomavirus (HPV) Testing in African American Women - Mississippi Delta

NCT03713710

COMPLETED Phase 2

Crushed Ticagrelor Versus Eptifibatide Bolus + Clopidogrel

NCT02925923

TERMINATED NA

Evaluation of Botulinum Toxin A Alone Versus Botulinum Toxin A With Hydrodistension for Treatment of Overactive Bladder

NCT02995967

TERMINATED NA

Image-Based Quantitative Assessment of Acute Radiation-Induced Changes in Glioma

NCT03168919

COMPLETED NA

Harvest for Health in Older Cancer Survivors

NCT02985411

COMPLETED NA

Simulated-altitude to Optimize Aerobic Exercise Among Breast Cancer Survivors With Limited Mobility

NCT03029182

TERMINATED Phase 2

Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma

NCT02837042

COMPLETED NA

Speed of Processing Training in Adults With HIV

NCT02758093

COMPLETED NA

Novel Methods for Ascertainment of Gout Flares -A Pilot Study

NCT02855437

COMPLETED NA

Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency

NCT02888171

COMPLETED NA

The Brave Initiative: Bringing Rehabilitation to American Veterans in an Enriched Environment

NCT02339220

COMPLETED NA

POWERSforID: A Telehealth Weight Management System for Adults With Intellectual Disability

NCT03139760

COMPLETED NA

Early Progressive Feeding in Human-Milk Fed Extremely Preterm Infants: A Randomized Trial

NCT02915549

COMPLETED NA

Diet Composition and Cardiometabolic Risk Reduction in Adults With SCI

NCT02630524

COMPLETED NA

Assessment of the Efficacy of the Aerodentis System

NCT03421886

COMPLETED NA

Smart Telehealth Exercise Intervention to Reduce COPD Readmissions

NCT03089853

COMPLETED NA

Effects of Botanical Microglia Modulators in Gulf War Illness

NCT02909686

COMPLETED

Impact of Pre-operative Steroids on Adrenal Insufficiency

NCT02956707

COMPLETED NA

Pilot Study for Investigating the Effect of the Bruder Eye Hydrating Compress on Contact Lens Discomfort in Contact Lens Wearers

NCT02848222

TERMINATED Phase 2

Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section

NCT03098420

COMPLETED Phase 3

Bupivacaine With Epidural Volume Extension

NCT03110003

COMPLETED Phase 1

Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors

NCT02835833

TERMINATED Phase 2

Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea

NCT03109418

COMPLETED NA

Ultrasound Assessment of Volume in Patients on Continuous Dialysis

NCT03194750

COMPLETED

Pharmacogenomic Profiling of Pediatric Patients

NCT02770339

COMPLETED NA

Treatment Outcomes of ReACT for PNES

NCT02801136

← Previous Page 15 of 24 Next →

Phase Distribution

PhaseTrial count
Phase 1 129
Phase 2 130
Phase 3 25
Phase 4 72

What is open in the University of Alabama at Birmingham pipeline

216 recruiting of 1,160 indexed (19% open); 723 completed (62%).

Phase mix: 97 late (III/IV) vs 259 early (I/II) (early-phase heavy).

Top condition: Obesity (15 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Alabama at Birmingham: open-pipeline peers nationwide

Peers matched on 1,160 registered trials and 19% open enrollment, not the therapeutic-area sidebar.

University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 15%16%17%18%19% Total trials Recruiting share University of Alabama at BirminghamNYU Langone HealthWake Forest University Health SciencesEmory UniversityNorthwestern UniversityUniversity of MinnesotaMclean HospitalChildren's Hospital Medical Center, CincinnatiArkansas Children's Hospital Research Institute
University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Alabama at Birmingham sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,160 trials (± recruiting share)

Sponsors near 19% open enrollment (± trial volume)

What to do with this University of Alabama at Birmingham page

1,160 registered trials is a research-attention snapshot, not an endorsement of University of Alabama at Birmingham or any single study.

  • 216 of University of Alabama at Birmingham's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Obesity is the condition University of Alabama at Birmingham studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Alabama at Birmingham pipeline card: 1,160 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.